iRhythm Technologies Q3 2025 Earnings Report

iRhythm Technologies EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.36
• Beat/Miss: N/A
• One Year Ago EPS: N/A

iRhythm Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $184.75 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

iRhythm Technologies Announcement Details

• Quarter: Q3 2025
• Date: 10/29/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, October 29, 2025
• Conference Call Time: 4:30PM ET

iRhythm Technologies (NASDAQ:IRTC), Inc. is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders. After wearing the water-resistant patch, patients mail it back to iRhythm’s central lab, where recorded data are analyzed using the company’s AI-powered architecture. A comprehensive report, including annotated ECG strips and rhythm diagnosis, is delivered directly to the prescribing clinician, helping to guide treatment decisions.

iRhythm primarily serves the United States market through partnerships with hospitals, clinics and diagnostic laboratories, and the company has been expanding its global footprint through strategic collaborations and regulatory approvals in select international markets. Leadership is headed by President and Chief Executive Officer Kevin King, who has overseen product innovation and process enhancements to support scalable growth. iRhythm continues to invest in research and development to extend its diagnostic platform into emerging areas of cardiovascular care and digital health.